BIAL INOVACAO RDI II

Projektträger – zwischengeschaltetes Finanzinstitut

BIAL PORTELA & CA SA

Ort

• Portugal

Beschreibung

The project concerns Bial’s R&D investment programme over the next 3 years.

Ziele

The promoter’s R&D investment program has the objective to discover, develop and provide therapeutic solutions in the following three major areas of research: central nervous system (CNS), cardiology and allergen immunotherapy.

Kommentar(e)

This would be Bial’s second R&D investment programme supported by the EIB.

Sektor(en)

• Industrie

Vorgeschlagene EIB-Finanzierung (voraussichtlicher Betrag)

EUR 45 million

Gesamtkosten (voraussichtlicher Betrag)

EUR 101 million

Umweltaspekte

The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorized for the same purpose and would therefore not require an EIA under the Directive 2011/92/EU. Full environmental details will be verified during the appraisal.

Auftragsvergabe

The promoter has been assessed by the EIB as being a private company not operating in the utilities sector and not having a status of a contracting entity, thus not being subject to EU rules on public procurement. However, if after the project appraisal, the EIB were to conclude that the promoter is after all subject to EU public procurement legislation (i.e. Directive 2004/17/EC), then the Bank would require the promoter to ensure that contracts for the implementation of the project have been/will be tendered in accordance with the relevant applicable EU procurement legislation (Directive 2004/17/EC and Directive 92/13/EEC), with publication of tender notices in the EU Official Journal, as and where required.

Projektstatus

Unterzeichnet - 21/09/2015